Shionogi reassured by latest clinical results for novel anti-allergic
This article was originally published in Scrip
Executive Summary
Shionogi is pressing ahead with a planned early Phase II programme in the US for its novel anti-allergic candidate S-555739, based on recent positive results from a Japanese trial.